Although some clinical studies have revealed adverse clinical and angiographic outcomes
of early-generation overlapping drug-eluting stents (DES), the safety and efficacy
of overlapping newer-generation DES for long narrowings have not been well established.
This study aimed to compare angiographic and 1-year clinical outcomes between a long
single stent (LSS) and overlapping double stents (ODS) in patients treated with newer-generation
DES for similarly long narrowings. We analyzed 8 to 10 months angiographic and 1-year
clinical outcomes of 112 lesions of 105 patients with long (30 to 38 mm) narrowings
treated with everolimus-eluting stent, a newer-generation DES, using LSS or ODS. We
divided our patients into LSS group (46 patients with 49 lesions) and ODS group (59
patients with 63 lesions). As a result, the rates of freedom from major adverse cardiac
events (92.9% vs 93.1%, p = 0.91) and target lesion revascularization (94.5% vs 95.1%,
p = 0.79) during 1-year follow-up were similar between the 2 groups. There was no
stent thrombosis observed between the 2 groups. In conclusion, everolimus-eluting
stent provided similar angiographic and 1-year clinical outcomes regardless of overlap
status in long narrowings.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.Circulation. 2005; 112: 3306-3313
- Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis.Circulation. 2004; 109: 634-640
- Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.JAMA. 2005; 294: 1215-1223
- Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses.Am J Cardiol. 2006; 98: 36-41
- Morphological predictors of restenosis after coronary stenting in humans.Circulation. 2002; 105: 2974-2980
- Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents.Circulation. 2005; 112: 270-278
- Classification and potential mechanisms of intravascular ultrasound patterns of stent fracture.Am J Cardiol. 2009; 103: 818-823
- Impact of stent overlap on angiographic and long-term clinical outcome in patients undergoing drug-eluting stent implantation.J Am Coll Cardiol. 2010; 55: 1178-1188
- Safety and efficacy outcomes of overlapping second-generation everolimus-eluting stents versus first-generation drug-eluting stents.Am J Cardiol. 2013; 112: 1093-1098
- Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program.Heart. 2013; 99: 626-633
- Impact of stent overlap on long-term clinical outcomes in patients treated with newer-generation drug-eluting stents.EuroIntervention. 2014; 9: 1076-1084
- Clinical end points in coronary stent trials: a case for standardized definitions.Circulation. 2007; 115: 2344-2351
- Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.N Engl J Med. 2005; 353: 653-662
- Tortuosity of coronary arteries: an indicator for impaired left ventricular relaxation?.Int J Cardiovasc Imaging. 2007; 23: 671-677
- Angiographic pattern of restenosis following implantation of overlapping sirolimus-eluting (Cypher) stents.Am J Cardiol. 2006; 97: 499-501
- Outcome of overlapping heterogenous drug-eluting stents and of overlapping drug-eluting and bare metal stents.Am J Cardiol. 2007; 99: 364-368
- Angioscopic findings of delayed healing at sites of sirolimus-eluting stent overlap after 21-month implantation.Int J Cardiol. 2008; 129: e10-e11
- Vascular response to overlapping everolimus-eluting stents. - comparison with paclitaxel-eluting stents.Circ J. 2010; 74: 1023-1025
- Different neointimal response to overlapping segments between everolimus-eluting stents and sirolimus-eluting stents—optical coherence tomographic study.Circulation. 2011; 124: A12546
- Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial.J Am Coll Cardiol. 2011; 58: 1325-1331
- Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV).Circulation. 2012; 125: 1246-1255
- Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial.Lancet. 2010; 375: 201-209
- Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.N Engl J Med. 2010; 362: 1663-1674
- Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.Circulation. 2012; 125: 2873-2891
- Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization.J Am Coll Cardiol. 2011; 57: 2143-2151
Article info
Publication history
Published online: March 17, 2016
Accepted:
March 1,
2016
Received in revised form:
March 1,
2016
Received:
December 8,
2015
Footnotes
See page 1727 for disclosure information.
Identification
Copyright
© 2016 Elsevier Inc. All rights reserved.
